Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AEOL 10150

Drug Profile

AEOL 10150

Alternative Names: AEOL-10150; MnTDEIP

Latest Information Update: 28 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duke University; National Jewish Medical and Research Center
  • Developer Aeolus Pharmaceuticals Inc; National Institutes of Health (USA); National Jewish Medical and Research Center; United States Army Medical Research Institute of Chemical Defense; University of Colorado at Denver
  • Class Oxidoreductases; Porphyrins; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Antioxidants; Free radical scavengers; Oxygen radical scavengers; Reactive oxygen species inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Acute radiation syndrome; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute radiation syndrome
  • Suspended Amyotrophic lateral sclerosis
  • No development reported Acute lung injury; Gastrointestinal disorders; Idiopathic pulmonary fibrosis; Lung disorders; Poisoning; Radiation injuries; Skin disorders; Solid tumours
  • Discontinued Chronic obstructive pulmonary disease; Cystic fibrosis; Diabetes mellitus; Mucositis; Spinal cord injuries; Stroke

Most Recent Events

  • 28 Mar 2019 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Acute-lung-injury in USA (SC)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top